Dite Gillian S, MacInnis Robert J, Bickerstaffe Adrian, Dowty James G, Allman Richard, Apicella Carmel, Milne Roger L, Tsimiklis Helen, Phillips Kelly-Anne, Giles Graham G, Terry Mary Beth, Southey Melissa C, Hopper John L
Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia.
Centre for Epidemiology and Biostatistics, The University of Melbourne, Victoria, Australia. Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):359-65. doi: 10.1158/1055-9965.EPI-15-0838. Epub 2015 Dec 16.
The extent to which clinical breast cancer risk prediction models can be improved by including information on known susceptibility SNPs is not known.
Using 750 cases and 405 controls from the population-based Australian Breast Cancer Family Registry who were younger than 50 years at diagnosis and recruitment, respectively, Caucasian and not BRCA1 or BRCA2 mutation carriers, we derived absolute 5-year risks of breast cancer using the BOADICEA, BRCAPRO, BCRAT, and IBIS risk prediction models and combined these with a risk score based on 77 independent risk-associated SNPs. We used logistic regression to estimate the OR per adjusted SD for log-transformed age-adjusted 5-year risks. Discrimination was assessed by the area under the receiver operating characteristic curve (AUC). Calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test. We also constructed reclassification tables and calculated the net reclassification improvement.
The ORs for BOADICEA, BRCAPRO, BCRAT, and IBIS were 1.80, 1.75, 1.67, and 1.30, respectively. When combined with the SNP-based score, the corresponding ORs were 1.96, 1.89, 1.80, and 1.52. The corresponding AUCs were 0.66, 0.65, 0.64, and 0.57 for the risk prediction models, and 0.70, 0.69, 0.66, and 0.63 when combined with the SNP-based score.
By combining a 77 SNP-based score with clinical models, the AUC for predicting breast cancer before age 50 years improved by >20%.
Our estimates of the increased performance of clinical risk prediction models from including genetic information could be used to inform targeted screening and prevention.
目前尚不清楚通过纳入已知易感性单核苷酸多态性(SNP)信息,临床乳腺癌风险预测模型能在多大程度上得到改进。
我们从基于人群的澳大利亚乳腺癌家族登记处选取了750例病例和405例对照,他们在诊断和招募时年龄分别小于50岁,均为白种人且非BRCA1或BRCA2突变携带者。我们使用BOADICEA、BRCAPRO、BCRAT和IBIS风险预测模型得出乳腺癌的绝对5年风险,并将这些风险与基于77个独立风险相关SNP的风险评分相结合。我们使用逻辑回归来估计对数转换后的年龄调整5年风险每调整标准差的比值比(OR)。通过受试者操作特征曲线下面积(AUC)评估辨别力。使用Hosmer-Lemeshow拟合优度检验评估校准情况。我们还构建了重新分类表并计算了净重新分类改善情况。
BOADICEA、BRCAPRO、BCRAT和IBIS的OR分别为1.80、1.75、1.67和1.30。与基于SNP的评分相结合时,相应的OR分别为1.96、1.89、1.80和1.52。风险预测模型的相应AUC分别为0.66、0.65、0.64和0.57,与基于SNP的评分相结合时分别为0.70、0.69、0.66和0.63。
通过将基于77个SNP的评分与临床模型相结合,预测50岁前乳腺癌的AUC提高了>20%。
我们对纳入遗传信息后临床风险预测模型性能提升的估计可用于指导靶向筛查和预防。